Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation

Talma Brenner*, Eran Nizri, Michal Irony-Tur-Sinai, Yasmine Hamra-Amitay, Itzhak Wirguin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The cholinergic network affects various cellular functions including neurotransmission, and immune reactions. In Myasthenia Gravis (MG), diagnosis and symptomatic therapy are based on cholinergic modulation by acetylcholinesterase inhibitors (AChEI). In Alzheimer's disease (AD) a neurodegenerative disorder associated with inflammatory pathology, cholinergic systems cell loss occurs early. Treatments with special AChEI enhance cholinergic transmission and may act as anti-inflammatory agent via immunocompetent cells expressing α-7 acetylcholine receptor (AChR). In Multiple Sclerosis (MS) an inflammatory T-cell-mediated disease, demyelination and neurodegeneration follow neuroinflammation. MS treatment includes anti-inflammatory and immunomodulatory drugs. AChEI can induce cholinergic up-regulation with subsequent effect on neuroinflammation via α-7-AChR expressing cells. These effects are additional to the cognitive benefit induced by AChEI.

Original languageEnglish
Pages (from-to)121-127
Number of pages7
JournalJournal of Neuroimmunology
Issue numberC
StatePublished - 15 Sep 2008
Externally publishedYes


  • Acetylcholinesterase inhibitors
  • Alzheimer's disease
  • Inflammation
  • Multiple Sclerosis
  • Myasthenia Gravis
  • α-7-Acetylcholine receptor


Dive into the research topics of 'Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation'. Together they form a unique fingerprint.

Cite this